Sylvia Fong
Scientific Advisory Group Member at Pathway to Cures
About
Independent consultant and adjunct professor specializing in gene therapy development. Pioneered the first approved AAV-based gene therapy for hemophilia A at BioMarin Pharmaceutical, bringing the program from research through regulatory approval with over 25 years of R&D experience.
Colleagues at Pathway to Cures
Amy L. Dunn
Chair, Medical and Scientific Advisory Council (MASAC) for NBDF at Pathway to Cures
Beth Whitehouse
NBDF Senior Vice President for Advancement at Pathway to Cures
Gilbert C. White
P2C Board Vice Chair & Secretary at Pathway to Cures
Glenn Pierce
Scientific Advisory Group Co-Chair at Pathway to Cures
Haiyan Jiang
Scientific Advisory Group Member at Pathway to Cures
Katherine High
Scientific Advisory Group Member at Pathway to Cures
Leonard Valentino
P2C Entrepreneur in Residence and CEO at Pathway to Cures
Michael Recht
Chair, P2C Scientific Advisory Group and Chief Medical and Scientific Advisor at Pathway to Cures